Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Patients that are able to receive CAR T-cell therapy have a potential for cure, however, many will not be qualified to receive therapy due to relapse. Bridging therapy is therapy intended to transition a patient from one therapy or medication to another or maintain their h

Trial Details

NCT ID
NCT06834373
Phase
PHASE2
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Chimeric Antigen Receptor T-Cell Therapy
  • Computed Tomography
  • Golcadomide
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Albert Lea, Minnesota, United States|43.64801,-93.36827
  • Mankato, Minnesota, United States|44.15906,-94.00915
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Age ≥ 18 years
  • Confirmed pathology diagnosis according to 2016 World Health Organization (WHO) classification including patients with diseases listed below with r…
  • Diffuse large B-cell lymphoma not otherwise specified (NOS) including:
  • Transformed lymphoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →